GLP-1 Receptor Agonists May Reduce CV and Thromboembolic Risks in Obesity and Autoimmune Disease: Study
USA: Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may provide important benefits for patients with both obesity and autoimmune diseases. In a real-world target trial emulation study with up to 10 years of follow-up, GLP-1 users experienced a 31% lower risk of pulmonary embolism (PE), a 17% lower risk of venous thromboembolism (VTE), a 13% lower risk of stroke or transient ischemic attack (TIA), and a 21% lower risk of emergency department visits compared with non-users.
- GLP-1 receptor agonist use was associated with a 13% lower risk of stroke or transient ischemic attack.
- Users had a 31% lower risk of pulmonary embolism.
- The risk of venous thromboembolism was reduced by 17%.
- Emergency department visits were 21% less frequent among GLP-1 users.
- All-cause mortality was 44% lower in patients receiving GLP-1 receptor agonists.
- The analysis also suggested potential benefits for myocardial infarction, although these associations were less definitive.
The researchers noted that variations in autoimmune disease severity and cardiovascular risk may have affected the findings. They also acknowledged the potential influence of unmeasured factors, including disease activity, socioeconomic status, and immunosuppressive therapy use. Additionally, the observational design could not determine the specific mechanisms underlying the observed benefits.
